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a b s t r a c t
The relationship between angular strain and (re)activity of bicyclic 2-azetidinones is still an open
question of major concern in the ﬁeld of penicillin antibiotics. Our study deals with original 13-
membered-ring 1,3-bridged 2-azetidinones related to the carbapenem family, and featuring a ‘‘planar
amide’’ instead of the ‘‘twisted amide’’ typical of penam derivatives. The bicycles 11 and 12 were
obtained from acetoxy-azetidinone 7, via the key-intermediate 10, by using the RCM (ring closing
metathesis) strategy. Theoretical predictions and experimental results of hydrolysis showed that the
large bicycle 12, endowed with high conformational ﬂexibility, is more reactive than the bicycle 11,
including a C]C bond of E conﬁguration, and the monocyclic 2-azetidinone precursor 10. The processing
of 2-azetidinones 10–12 in the active site of serine enzymes has been computed by ab initio methods,
considering three models. Due to geometrical parameters of the enzymic cavity (nucleophilic attack from
the a-face), precursor 10 was predicted more active than 11 and 12 in the acylation step by Ser–OH.
Indeed, bicycles 11 and 12 are modest inhibitors of PBP2a, while 10 is a good to excellent inhibitor of
PBP2a and R39 bacterial enzymes.
 2008 Elsevier Masson SAS. All rights reserved.
1. Introduction
Antibiotics of the penicillin family are characterized by the
presence of a b-lactam ring involved into a quite rigid bicyclic
structure (Scheme 1, 1 and 2). It is widely accepted that the high
reactivity of b-lactam antibiotics results from the lack of amide
resonance in the 2-azetidinone ring [1–3]. In penams (1), penems
(2, X¼ S) and carbapenems (2, X¼CH2), the p electrons of the N–
C]O function cannot be delocalized over the three atoms owing to
the structural constraints which prevent the amide substituents to
lie in the same plane. The deviation versus coplanarity (i.e. pyr-
amidality of the bridge-head nitrogen atom) is usually expressed by
Woodward’s [4–6] or Burton’s [7] parameters.
The experimental and theoretical interest of the scientiﬁc
community in the so-called ‘‘twisted amides’’ [8] has been constant
since more than 60 years, as exempliﬁed with the recent achieve-
ment of the 2-quinuclidone (3) synthesis in 2006 [9]. In the ﬁeld of
antibiotics, [2] a lot of works has been devoted to the search of more
strained, fused bicyclic b- [10,11] and g- [12,13] lactam systems.
However, there is still no clear relationship between the lactam
structural features (N-pyramidality, bond angles and distances),
chemical reactivity and biological activity.
Our aim is to explore a totally different route for designing
reactive bicyclic b-lactams. During the 2-azetidinone ring opening
under nucleophilic attack (basic hydrolysis or processing by
a serine enzyme), an important conformational reorganisation of
the other ring has to occur. The conformational ﬂexibility of this
second ring, namely the capacity to adjust itself to new geometrical
parameters, should decrease the activation barrier of the b-lactam
N1–C2 bond cleavage. To investigate this idea, we decided to
prepare large ring 1,3-bridged b-lactam compounds (Scheme 2)
and to study their reactivity, theoretically and experimentally. In
contrast with fused lactams, bridged lactams as potential antibi-
otics are scarcely described in the literature; we found only three
relevant examples corresponding to skeletons 4 [14], 5 [15] and 6
[16], but these structures display high angular strain and therefore,
twisted amide bonds (Scheme 1).
In this article, we illustrate the study of conformationally ﬂex-
ible 1,3-bridged b-lactams with the 13-membered-ring compounds
11 and 12 (Scheme 3) derived from acetoxy-azetidinone 7,
commonly used as precursor of thienamycin derivatives (carbape-
nem family) [17]. We selected RCM reaction (Ring Closing
Metathesis) [18–20] as key-step for forming the large ring
(Scheme 2), the required precursor being readily accessible by
sequential functionalisation of nitrogen N1 and deprotected
hydroxyl group on C5. We chose acylation reactions to introduce
the two side-chains for the following reasons: (i) the synthetic
easiness providing a rapid access to compounds of interest; (ii) the
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potential biological activities of the novel b-lactams, since N1-
acylated compounds have been previously recognized as inhibitors
of various proteases [21–24].
A complete comparative study of the chemical and biochemical
reactivity of b-lactams 10–12 has been performed. Theoretical
predictions could be experimentally conﬁrmed, that pointed out
the importance of conformational ﬂexibility. Moreover, interesting
activities for the inhibition of serine enzymes were recruited.
2. Results and discussion
2.1. Synthesis (Scheme 3)
Commercially available (3R, 4R, 5R) chiron 7 was transformed
into precursor 10 in three steps with an overall yield of 72%. N-
Acylation with 4-pentenoyl chloride was conducted in reﬂuxing
dichloromethane (DCM), in the presence of pyridine. Silyl ether
deprotection of 8 was not effective by using cesium ﬂuoride in
methanol, and gave poor yields by using tetrabutylammonium
ﬂuoride in aqueous acetic acid and THF solution [25]. The protocol
established byMurakami et al. [26] for the synthesis of oxacephems
afforded the best results: alcohol 9 was quantitatively obtained by
treatment of 8 with HCl–AcOH in acetonitrile at 0 C. The purity of
crude 9, controlled by 1H NMR, was judged adequate to directly
perform the next step. Thus 10 resulted from the reaction of crude
alcohol 9 with 4-pentenoyl chloride and pyridine in DCM at room
temperature. After chromatographic puriﬁcation, the product was
recovered in 90% yield.
The RCM key stepwas readily performed under Ahn’s conditions
[27], i.e. with Grubbs catalyst of second generation (5 mol%), in
diluted solution of 10 (5 mM in DCM), at room temperature. Only
one cyclized compound was formed (TLC and NMR analysis of the
crude mixture) corresponding to 11 with the E conﬁguration of the
C]C double bond (JH,H¼ 15.5 Hz). Puriﬁcation by column chro-
matography on silica gel afforded 85% yield of 11 which structure
was conﬁrmed by X-ray diffraction analysis of a single crystal
shown in Fig. 1. The main bond lengths, angles, torsions and
distances from the plan, characteristic of the bicycle 11, are
summarized in Table 1.
Finally, catalytic hydrogenation led quantitatively to the satu-
rated bicyclic azetidinone 12.
All the spectroscopic data (Section 4) indicated that the azeti-
dinones 10–12 are ‘‘non-twisted’’ amides (Table 2). The IR spectra
showed very similar values of carbonyl stretching frequencies for
monocyclic (10) and bicyclic compounds (11 and 12). The b-lactam
protons H3 and H4 also displayed the same pattern for the three
compounds 10–12, but differences arose for H5 proton of the 1-
hydroxyethyl side-chain between monocyclic (10) and bicyclic
b-lactams (11, 12). However, the two bicyclic derivatives are quite
similar considering the dihedral angle H4–C4–C5–H5 (see J values).
The 13C chemical shifts of the C]O functions were found to be
almost identical in compounds 10–12. The X-ray structure of 11
(Fig. 1) conﬁrmed the planarity of the amide b-lactam bond. The
typical features of 11 compared to classical penicillins (penams 1
[28] and penems 2 [29]) are summarized in Table 3: the large ring

































































Scheme 3. Synthesis of 13-membered 1,3-bridged 2-azetidinone. a) Cl-CO–(CH2)2–
CH]CH2, pyridine, CH2Cl2, reﬂux or 20 C; b) HCl–AcOH (5:7), CH3CN, 0 C; c) Grubbs

















Scheme 1. Bicyclic lactams with ‘‘twisted amide’’ bond (skeletons are drawn with
omitting the substituents).
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2.2. Conformational study – heat of formation
A lot of conformers can exist for the monocyclic molecule 10.
Considering rotations around N1–C6, C4–O7 and C3–C5 bonds (see
numbering of Scheme 3), and a minimum of 2 conformers per
rotations, at least 8 conformers could be drawn! In the bicyclic
compounds 11 and 12, rotation around C3–C5 being suppressed,
a minimum of 4 conformers could be associated with each struc-
ture. This has been examined by ab initio calculations in vacuum
(B3Lyp with the double basis set 6-31G(d)). Several conformers of
the precursor 10, the 1,3-bridged compound 11 with E or Z
conﬁguration of the double bond, and ﬁnal compound 12 have been
localized on the potential energy surfaces. Three representative
conformers are pictured in Scheme 4 and shown in Fig. 2 for
compound 11. In conformer I, the two imide carbonyls are aligned
and the 13-membered bridge unfolds up to the b-face of the four-
membered ring. A complete turning of the C3 thienamycin-like
side-chain gives rise to the more stable conformer II with the large
cycle covering the azetidinone a-face. The same situation is found
in the most stable conformer III, but with an antiparallel arrange-
ment of the C2 and C6 carbonyls. For all conformers, the E stereo-
isomer appears more stable than the Z one (see Scheme 4).
Conformer III (E conﬁguration) is precisely the one rooted in the
crystalline solid state of 11 (Figs. 1 and 2).
In solution, the coexistence of conformers for the bicycle 11 (or
12) was not experimentally visible by NMR spectroscopy. However,
conformers were detected in the case of the monocyclic precursor
10. 1H NMR spectrum recorded in D2O (25 C, addition of 5% d6-
DMSO for complete dissolution) showed two set of signals in the
3:1 ratio: 6.55 d and 6.31 d for H4, 5.33 d and 5.21 d for H5, 3.74 d and
3.38 d for H3, 2.13 d and 2.00 d for MeCO2, 1.35 d and 1.29 d for
MeCH5 (Fig. 3). Coalescence occurred at 72 C, giving the same
pattern as the spectrum recorded in CDCl3 at 25 C (see Section 4).
The heat of formation of 11 by RCM reaction was calculated for
both stereoisomers, E and Z, by reference to the open precursor 10
minus ethylene, in the respective conformations I–III (Table 4). The
E stereoisomer was found to be more stable than the Z one, in
agreement with the experimental results (NMR and X-ray data). For
all considered conformers, cyclisation of 10 into E-11 is favoured by
about 5–7 kcalmol1. The reaction is slightly endothermic in the
case of conformer III in which the ester function (C3 side chain) is
orientated on the outside of the b-lactam ring and the carbonyl
dipoles of the imide function are opposite.
2.3. Reactivity towards hydroxyl anion
Basic hydrolysis of b-lactams has been intensively studied,
theoretically [30–34] and experimentally [35,36]. Ring opening is
a two-step process involving (i) the formation of a tetrahedral
intermediate by nucleophilic addition of OH onto the azetidinone
carbonyl C2 atom, followed by (ii) the cleavage of the N1–C2 bond,
this second step being the rate determining one.
Heat of formation and structure of the tetrahedral intermediates
obtained by addition of OH onto the b-lactam C]O bond of 10–12
(conformer III) have been calculated and compared to a penam
reference (Table 5). The N1–C2 bond length is indicative of the
intrinsic reactivity of the studied structures: the longer bonds
correspond to the more reactive azetidinones. Thus the predicted
order of reactivity versus OH is as follows: 12>11>10. However,
our compounds appeared less reactive than the strained penam
derivative. The computational results are interesting since the
simple chemical ‘‘intuition’’, in this special case, could not be reliable.
Fortunately, the previous order of reactivity could be experi-
mentally conﬁrmed, thus establishing the validity of our compu-
tational approach. Basic hydrolysis of azetidinones 10–12 was
Table 1
X-ray data for 11 (for atom numbering, see Fig. 1).
Lengths (Å) Angles and torsions () Distancesb (Å)
N1–C13 1.395 (4) C13–N1–C14 93.5 (2) *O22 þ0.011
N1–C14 1.465 (4) C14–N1–C2 127.6 (3) *C13 þ0.034
C14–C12 1.534 (4) C13–N1–C2 137.4 (3) *N1 0.056
C13–C12 1.513 (5) C13–N1–C14-C12 2.1 (2) *C2 0.041
C13–O22 1.200 (4) C2–N1–C13–O22 9.9 (6) *O15 þ0.052
N1–C2 1.382 (4) C13–N1–C2–O15 169.1 (3) C12 þ0.225
C2–O15 1.206 (4) C2–N1–C14–C12 169.9 (3) C14 þ0.172
C6–C5 1.275 (6) C4–C5–C6–C7 173.0 (4) ha 0.096
a N1 distance, in the middle of the calculated plan from atoms linked to N1.





1H NMR (d, mult., J)b
(500 MHz, CDCl3, ppm)
13C NMR (C]O carbons)c
(125 MHz, CDCl3, ppm)
10 1806, 1742, 1722 6.48 (d, 1.6 Hz), 3.28
(dd, 1.6; 5.8 Hz),
5.29 (dq, 1.8; 6.4 Hz)
162.2, 168.8, 169.2, 171.7
11 1809, 1742, 1716 6.53 (d, 1.6 Hz), 3.19
(dd, 1.6; 1.8 Hz), 5.58
(dq, 1.8; 6.7 Hz)
163.0, 169.1, 170.7, 171.6
12 1807, 1743, 1716 6.50 (d, 1.5 Hz), 3.20
(dd, 1.5; 1.7 Hz), 5.53
(dq, 1.7; 6.9 Hz)
163.5, 169.0, 171.1, 171.9
a n Values are given in the following order: b-lactam, ester and lactone, imide
carbonyl functions.
b dValues are given in the followingorder: H4,H3 andH5 (numbering of Scheme3).
c d Values are given in the following order: C2, OAc, C6, lactone (numbering of
Scheme 3).
Table 3
Structural features of b-lactams from X-ray data.
Cmpd ha (Å) Bond lengthb (Å)
N1–C2; C2]O
Bond angleb (Å) C2–N1–C4;
C4–N1–C6; C2–N1–C6
qc ()
11 0.096 1.395; 1.200 93.5; 127.6; 137.4 1.5
Penam [21] 0.38 1.383; 1.206 94.26; 117.24; 125.85 22.65
Penem [22] 0.42 1.383; 1.224 90.55; 113.81; 126.28 29.36
a h, Woodward’s parameter (perpendicular distance of the nitrogen N1 from the
plane of its three substituents).
b the numbering of compound 11 (see Scheme 3) was used for Penam and Penem
representatives.
c q, Burton’s parameter (torsion angle measured as 360 minus the sum of the
three contiguous angles around N1).
Fig. 1. X-ray structure of 11 (ORTEP view).
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performed in D2O at pD¼ 8 (4 mM solution containing 5%
d6-DMSO, 25 C) and followed by 1H NMR at 500 MHz. Disap-
pearance of the starting materials (% SM) as a function of time
(min), clearly showed that 12 reacts faster than 11, and 11 faster
than 10 (Fig. 4). Half-life times (t1/2) are respectively about 4 h, 6 h
and 16 h. Azetidinone ring opening (N1–C2 cleavage) resulted in
a signiﬁcant shielding of the H3 and H4 protons used as internal
probes. No competition with acetate (on C4), or lactone (on C5)
hydrolysis could be detected, since chemical shifts of CH3 and H5
were almost unchanged. N1–C6 cleavage of the imide function was
not observed (control of the chemical shift of CH2 next to C6), in
agreement with a previous study of Page devoted to N-benzoyl b-
lactams [37].
2.4. Reactivity versus serine enzyme models
A concerted mechanism of b-lactam hydrolysis, in neutral
medium, could be considered as the simplest model of serine-
enzyme machinery [38]. In model A (Scheme 5), the nucleophile is
formed by the duplex H2O–H2O: the second water molecule acts as
a proton carrier of the ﬁrst water molecule to the nitrogen of the
b-lactam function. Two more complex catalytic models have been
used in this study, featuring two types of nucleophilic environment.
Inmodel B (Scheme 5), the catalytic machinery of the chymotrypsin
family is mimicked. The triad formed by Ser-195, His-57 and Asp-
102 has been replaced with the triplex 2-formylamino-1-ethanol-
H2O-imidazole. In this model, the hydrogen of the serinemimicry is
transferred to the b-lactam nitrogen via a water molecule which
interacts with the imidazole ring [39,40]. The mechanism of class-A
b-lactamases has been drawn in model C (Scheme 5). In these
enzymes, the nucleophilic serine Ser-70 is surrounded by Glu-166,
Lys-73 and Ser-130. In order to limit the inﬂuence of the global
charge on model C, methylamine mimicking Lys-73 is neutral as
this aminoacid forms a zwitterionwith Glu-166. Ser-70 and Ser-130
have been replaced with 2-formylamino-1-ethanol and methanol
respectively [41]. In both models B and C, the formamide moiety
mimicks the oxyanion hole stabilization.
The reactivity of b-lactams 10–12 has been computed at the RHF
level with theminimal basis set MINI-10; this is imposed by the size
of the analyzed systems which involve about 70 atoms [42]. For
model A, both approaches of the azetidinone ring have been
considered, on the a-face and the b-face of the cycle. For models B
and C, only the nucleophilic attack on the a-face has been
computed because this approach is the relevant one [43] in the
active site of elastases (model B) and class A beta-lactamases
(model C). Results are collected in Table 6.
The order of reactivity found for nucleophilic attack by (H2O)2
from the less hindered b-face (model A, ﬁrst column) was almost
the same as for basic hydrolysis, i.e. 12>11>10, independently of
the conformer considered, with DE values ranging from 26.7 to
19.6 kcalmol1 (conformer II) and 29.8 to 28.7 (conformer III). The
13-membered ring 1,3-bridged compounds 11 and 12 showed
reactivities of similar order of magnitude as the penam compound
attacked from the a-face (DE¼ 26.6 kcalmol1). However, this way
of nucleophilic attack appeared to be highly unfavourable for the
bicyclic azetidinones 11 and 12 in conformation III (model A,
second column), with DE values of 49.1 kcal mol1 and
51.3 kcalmol1, respectively. Considering the chymotrypsin model
(model B, third column), the penam reference was found highly
reactive (DE¼ 14.6 kcal mol1), but not the bridged compounds 11
and 12 in the most stable conformation III (DE¼ 39.2 and
43.1 kcal mol1). Due to the size of the nucleophilic triplex in the
b-lactamase model (model C, fourth column), conformation III of
the bicyclic azetidinones 11 and 12 was no more accessible; at the
transition state, the imide carbonyl turned to give the conformation























Scheme 4. Three localized conformers of 10–12. Energy differences (kcal mol1) between conformers 11 are given as a function of the C]C double bond conﬁguration.
Fig. 2. Structures of calculated conformers of 11 (E isomer).
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reactive (DE¼ 17.6 kcalmol1) than our large ring bridged
compounds (DE¼ 35.2 and 50.9 kcalmol1). In fact, the unfolding
of this ring, in the most stable conformers, hides the a-face of the
reactive four-membered ring, thus handicapping the nucleophilic
attack. This is not the case for the monocyclic precursor 10which is
predicted to be more reactive versus serine enzymes (models B and
C) than both 11 and 12. Moreover, the conformation of the acetate
substituent (on C4) could play an indirect, but probably decisive
role in the transition state stabilisation. Indeed, perturbations of the
H-bonding network in the enzymic cavity were found depending
on the orientation of this group. This is illustrated on Fig. 5 showing
two conformers III of 10, different at the level of the OAc substit-
uent, processed in model C. When the acetate carbonyl was
oriented outside versus the b-lactam ring (structure b), the meth-
anol molecule of the nucleophilic triplex moved in order to create
H-bonding interaction with this function, at the transition state.
Such a phenomenon was not detected when the acetate carbonyl
pointed inside versus the b-lactam ring (structure a).
The theoretical study of 10–12 reactivity towards models of
serine enzymes emphasized the huge complexity of our systems,
precisely due to their conformational ﬂexibility. It is also important
to note that only the acylation step has been computed, although
the complete catalytic process involves three successive steps: the
recognition step (formation of a Michaelis complex), the acylation
step (formation of an acyl-enzyme intermediate), and the deacy-
lation step (hydrolysis of the acyl-enzyme intermediate) [44,45].
Taking into account the limitations of our models, it seems
nevertheless that the bridged b-lactams 11 and 12 could interact
with serine enzymes, under selected conformations (some DE
values are around 30 kcalmol1), but that the monocyclic
precursor 10 should be more active. This has been tested
experimentally.
2.5. Biochemical evaluation
As representative enzyme of the chymotrypsin family (model B),
we have considered PPE (porcine pancreatic elastase). The capacity
of several b-lactam antibiotics [46,47] and monocyclic b-lactams
[48–52] to inhibit elastase has been previously reported.
Compounds 10–12 were evaluated for their inhibitory effect on
PPE, in a competition experiment with N-succinyl-L-alanyl-L-
alanyl-L-alanyl-p-nitroanilide as substrate. The rates of PPE-cata-
lyzed hydrolysis of the substrate were determined, in the presence
of different concentrations of tested compounds (from 0.1 mM to
100 mM), thanks to the measurement of UV-absorbance (A) at
410 nm (formation of p-nitroaniline) recorded as a function of time.
The monocyclic b-lactam 10 was active at 1 mM (Fig. 6), but the
bicyclic b-lactams 11 and 12were still inactive at 100 mM. The active
Fig. 3. 1H NMR spectrum of 10.
Table 4
Heat of formation of 11 in kcal mol1 (B3Lyp/6-31G(d)).
DE of E-isomer/Z-isomer
Conformer I 6.01 11.49
Conformer II 7.29 14.03
Conformer III 2.76 7.09
Table 5
Tetrahedral intermediates formed by addition of OH- onto the b-lactam C]O bond
of 10, 11 and 12 in conformer III and Penam (B3Lyp/6-31G(d)).

























Fig. 4. Rate of hydrolysis of 10–12.
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compound 10 behaved as a ‘‘slow substrate’’ or ‘‘reversible inhib-
itor’’. Indeed, after pre-incubation of PPE with 10, at different
concentrations (1, 25, 50, 100 mM) and various times (20, 40,
60 min), followed by dilution with the substrate solution, the
enzyme recovered slowly its activity (Fig. 7).
Our compounds were also tested against bacterial enzymes
(model C), one class-A b-lactamase (TEM-1) and representative
PBPs (Penicillin Binding Proteins). Indeed, our reactivity model of
serine b-lactamases mimicks the entities involved during the
acylation mechanism, namely Ser-70, Lys-73 and Ser-130. These
amino acids are also present in the active site of D,D-peptidases, as
proven by crystallographic studies of Actinomadura R39 [53] and
Streptomyces K15 [54].
The potential inhibition of TEM-1 by b-lactams 10–12 was eval-
uated as above, in competition experiments with a chromogenic
substrate (nitroceﬁne), but none of the compoundswas found active
at 100 mM. R39 is a model enzyme of low molecular weight D,D-
peptidases [53]. TheotherconsideredPBPsarehighmolecularweight
Table 6


















10 (I) – – 28.91 37.41
10 (II) 26.72 33.10 – –
10 (III) 29.69 41.30 30.81 32.75
11 (I) – – 26.47 38.29
11 (II) 24.46 37.22 – 35.17
11 (III) 29.83 49.07 39.22 –
12 (I) – – 30.78 36.28
12 (II) 19.61 34.84 – 50.89
12 (III) 28.70 51.33 43.16 –
Penam / 26.56 14.62 17.59
a Deﬁnition of nucleophilic attack from a-face or b-face.




































Model A: H2O-H2O duplex (concerted chemical hydrolysis at pH 7)
Model B: 2-formylamino-1-ethanol + H2O + imidazole
(model of elastase with Ser-195 and His-57)
Model C: 2-formylamino-1-ethanol + MeNH2 + MeOH
(model of PBPs with Ser-70, Lys-73 and Ser-130)



















Fig. 6. Inhibition of PPE by azetidinone 10.
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enzymes responsible for bacterial resistance to b-lactam antibiotics:
[55–57] PBP2a from Staphylococcus aureus ATCC433000 [58,59],
PBP5fm from Enterococcus faecium [60], and PBP2x from Streptococcus
pneumoniae 5204 [61–63]. The peptidases (0.8 or 2.5 mM) and the
azetidinones 10–12 (100 mM) were incubated during 16 h, then
ﬂuorescent ampicillin (25 mM)was added. After 45 min, the proteins
were denaturated, and the ﬂuorescence intensity (resulting from the
covalent protein–ampicillin complexes) was measured. In this
protocol, the tested compoundswere supposed tobeableof acylating
the PBPs, and the residual activities of the proteins were thus deter-
mined. Results of Table 7 are expressed in percentages of initial
activity. Thus low % values indicate very active compounds. Benzyl-
penicillin (Pen G), used as positive control, showed values of about
5–10%. Themonocyclic azetidinone 10was highly active against R39,
moderately active against PBP2a, and weakly active against PBP5fm.
The bicyclic azetidinones 11 and 12were weakly active only against
PBP2a. None of the compounds inhibited PBP2x. In opposition to the
chemical reactivity, the biochemical tests pointed out azetidinone 10
as the most active compound. Nevertheless promising activities of
azetidinones 11 and 12 were recruited versus PBP2a, a clinically
relevant target of MRSA strains.
3. Conclusions
We have explored a non-traditional approach for designing
reactive b-lactams, and possibly new antibacterial agents. Instead
of increasing the angular strain and the N1 pyramidality (‘‘twisted
amide’’) in the azetidinone ring of 1,4-fused bi- [64,65] or tricyclic
systems [66], we considered ﬂexible 1,3-bridged bicyclic systems
featuring a ‘‘planar amide’’ and a large ring susceptible to generate
a lot of conformers. Such azetidinones, endowed with a thienamy-
cin-like side-chain at C3 and the related stereochemistry at C3–C5,
are readily accessible via a convergent RCM strategy, as illustrated
by the synthesis of the 13-membered bicycles E-11 and 12 from the
commercial chiron 7, precursor of 10. The experimental structural
data (IR and NMR spectroscopic analyses and X-ray diffraction)
conﬁrmed that b-lactams 10–12 are well planar amides. Theoretical
analysis of our novel systems revealed that their reactivity towards
nucleophiles (OH, H2O–H2O) and serine enzymes (models B and
C) indeed depends signiﬁcantly on the considered conformers.
The chemical reactivity of compounds 10–12 could be correctly
predicted by ab initio calculations, regarding their half-live times in
phosphate buffer. Both bicyclic azetidinones 11 and 12 are more
reactive than their monocyclic precursor 10, probably because
some angular strain still operates in the 13-membered bridged
series. The enhanced reactivity of 12 (saturated large cycle) versus
11 (C]C double bond with E-conﬁguration in the large ring) can
result from torsion (or eclipse) strains and transannular interac-
tions which become more important when carbon atoms with sp2
geometry are transformed into the sp3 one.
The reactivity of azetidinones 10–12 versus serine enzymes
appeared hardly predictable by theoretical tools. Nevertheless, the
crucial role of geometrical factors (‘‘up’’ or ‘‘down’’ nucleophilic
attack of the b-lactam carbonyl) has been pointed out. Conse-
quently, the monocyclic precursor 10 seems to be more capable of
ﬁtting within an enzymic cavity than the bicycles 11 and 12.
Experimentally, we found that 10 behaves as a good inhibitor of
a mammalian elastase. The slow (and partial) reversibility of this
inhibition is reminiscent of the mechanism of action of clavulanic
acid and 6-b-bromopenicillanic acid versus class A b-lactamases
(such inhibitors are called ‘‘passive covalent inhibitors’’) [67,68].
Also, 10 was an excellent inhibitor of the bacterial D,D-peptidase
R39. This result abolishes an old dogma in the ﬁeld of penicillin-
type antibiotics, i.e. the need of a carboxylic function on the
substrate/inhibitor for promoting a good interaction with PBP
enzymes. Yet, the most stimulating biochemical result was the
discovery of novel inhibitors of PBP2a featuring non-traditional
structures: their activities are moderate (10) to modest (11) and
weak (12), but well measurable.
The emergence of penicillin-resistant bacterial strains and the
recent dramatic increase of those strains, all over the world,
represent a major concern in medicine. Particularly, the prevalence
of MRSA (methicillin-resistant Staphylococcus aureus) in hospitals
has stimulated the development of more potent carbapenems (ME
1036 [64]) and cephalosporins (PPI 0903M [65]), characterized by
very bulky substituents on the bicyclic skeletons. The lethal action
of such antibiotics is due to their high afﬁnity for PBP2a. The
development of large ring 1,3-bridged 2-azetidinones, structurally
related to the carbapenem family (2-hydroxyethyl side chain on C3
and thienamycin stereochemistry) and the cephalosporin family
(acylamino side chain on C3 and penicillin stereochemistry), is
currently continued in our laboratory.
The present preliminary results pave the route of a possible




Manipulations were performed under an argon atmosphere in
ﬂame-dried glassware. Reagents were used as-received and solvents
were dried by standard procedures. TLC analyses were performed
on aluminium plates coated with silica gel 60 F254 (Merck) and
visualized with UV (254 nm) and KMNO4 solution. Melting points
were measured on Electrothermal apparatus calibrated with ben-
zoic acid (uncorrected m.p.).Column chromatographies were per-
formed on silica gel Merck 60 (40–60 mm). NMR spectra were
recorded on a Bruker Avance 500 spectrometer at 500 MHz (1H) and
175MHz (13C) in CDCl3 with TMS as an internal standard. IR spectra
were recorded on Shimadzu FTIR-8400S spectrometer; compounds
were deposited on NaCl plates as a thin ﬁlm by evaporation from
CH2Cl2 solution. High Resolution MS were obtained in the Mass




















Fig. 7. Reversibility of PPE inhibition by 10 (60 min incubation).
Table 7
Inhibition of bacterial enzymes. Results are given as percentages of initial activity.
Cmpda R39 (0.8 mM) PBP2a (2.5 mM) PBP5fm (2.5 mM) PBP2x (0.8 mM)
10 14 2 66 14 84 12 93 6
11 96 4 86 8 104 4 116 5
12 113 18 94 3 113 11 99 4
Pen G ndb 13 3 10 3 <5
a Compounds were tested at 100 mM.
b Not determined.





To a stirred solution of acetoxy-azetidinone 7 (500 mg,
1.74 mmol) in dry CH2Cl2 (15 mL) were added pyridine (0.28 mL,
3.48 mmol) and 4-pentenoyl chloride (0.38 mL, 3.48 mmol). The
solution was heated at 35 C under an argon atmosphere for 65 h.
Then the reaction mixture was diluted with CH2Cl2 (50 mL) and
successively washed with a 3.3 M HCl solution (50 mL), a saturated
NaHCO3 solution (50 mL) and brine (50 mL). The organic phase was
dried over MgSO4 and concentrated under vacuum. The residue
was puriﬁed by ﬂash chromatography (cyclohexane/EtOAc 10:1) to
furnish imide 8 as a pale yellow oil (515 mg, 80%). Rf¼ 0.57
(cyclohexane/EtOAc 5:2); 1H NMR: d¼ 6.58 (d, J¼ 1.6 Hz, 1H; H4),
5.82 (ddt, J¼ 6.5, 10.5, 17.2 Hz, 1H; CH]CH2), 5.08 (dd, J¼ 1.6,
17.2 Hz, 1H; CH]CH2), 5.01 (dd, J¼ 1.6, 10.5 Hz, 1H; CH]CH2), 4.29
(qd, J¼ 2.5, 6.7 Hz, 1H; H5), 3.12 (dd, J¼ 1.6, 2.5 Hz, 1H; H3), 2.81
(td, J¼ 7.6, 16.9 Hz, 1H; CO–CH2), 2.74 (td, J¼ 7.6, 16.9 Hz, 1H; CO–
CH2), 2.40 (td, J¼ 6.5, 7.6 Hz, 2H; CH2–C]C), 2.10 (s, 3H; COCH3),
1.31 (d, J¼ 6.7 Hz, 3H; CH3–CH–O), 0.82 (s, 9H; SitBu), 0.03 (s, 3H;
SiCH3), 0.07 (s, 3H; SiCH3);
13C NMR: d¼ 169.1 (C6), 168.9 (OCOMe),
164.4 (C2), 136.2 (CH]C), 115.8 (C]CH2), 74.1 (C4), 65.0 (C3), 64.1
(C5), 35.6 (COCH2), 27.4 (CH2C]), 25.5 (C(CH3)3), 21.7 (CH3CH–O),
20.8 (CH3CO2), 17.6 (C(CH3)3), 4.3 (SiCH3), 5.5 (SiCH3); IR:
n¼ 1808, 1759, 1721, 1642, 1306 1; HR-ESI-TOF-Mass (positive-
mode):m/z calcd for C18H31NO5SiþNa: 392.1869; found: 392.1863.
4.2.2. 1-(Pent-4-enoyl)-(3R,4R)-3-[1(R)-hydroxyethyl]-4-
(acetoxy)-azetidin-2-one (9)
b-Lactam 8 (850 mg, 2.3 mmol) dissolved in CH3CN (100 mL)
was treated with 17 M AcOH (0.95 mL, 16.1 mmol) and 12 M HCl
(0.96 mL, 11.5 mmol) at 0 C for 3 h. The solvent was removed
under vacuum and the residue diluted with EtOAc (50 mL). The
organic phase was washed with a 10% Na2CO3 solution and brine
(2 50 mL), then dried over MgSO4 and concentrated. The crude
alcohol was puriﬁed by ﬂash chromatography (cyclohexane/EtOAc
5:3) to yield 9 as a pale yellow oil (490 mg, 83%). Compound 9 can
also be used without puriﬁcation in the next step. Rf¼ 0.40
(cyclohexane/EtOAc 5:3); 1H NMR: d¼ 6.33 (d, J¼ 1.4 Hz, 1H; H4),
5.72 (ddt, J¼ 6.8, 10.3, 17.1 Hz, 1H; CH]CH2), 4.98 (dd, J¼ 1.5,
17.1 Hz, 1H; CH]CH2), 4.91 (dd, J¼ 1.5, 10.3 Hz, 1H; CH]CH2), 4.13
(qd, J¼ 5.4, 6.4 Hz, 1H; H5), 3.30 (br s, 1H; OH), 3.08 (dd, J¼ 1.4,
5.4 Hz, 1H; H3), 2.70 (m, 2H; CO–CH2), 2.30 (td, J¼ 6.8, 7.4 Hz, 2H;
CH2–C]C), 2.02 (s, 3H; COCH3), 1.24 (d, J¼ 6.4 Hz, 3H; CH3–CH–O);
13C NMR: d¼ 169.9 (C6), 169.5 (OCOCH3), 163.3 (C2), 136.0 (CH]C),
115.8 (C]CH2), 75.2 (C4), 64.9 (C3), 63.8 (C5), 35.6 (COCH2), 27.4
(CH2–C]C), 20.9 (CH3CHO), 20.7 (CH3CO2); IR: n¼ 3501,1805,1755,
1718,1641,1311 cm1; HR-ESI-TOF-Mass (positive-mode):m/z calcd
for C12H17NO5þNa: 278.1004; found: 278.0992.
4.2.3. 1-(Pent-4-enoyl)-(3R,4R)-3-[1(R)-(pent-4-enoyloxy)-ethyl]-
4-(acetoxy)-azetidin-2-one (10)
To a stirred solution of b-lactam 9 (800 mg, 3.14 mmol) in dry
CH2Cl2 (20 mL) were added pyridine (0.38 mL, 6.28 mmol) and 4-
pentenoyl chloride (0.69 mL, 6.28 mmol). The reaction was per-
formed at room temperature under an argon atmosphere for 3 h.
The mixture was diluted with CH2Cl2 (50 mL) and successively
washed with a 3.3 M HCl solution (50 mL), a saturated NaHCO3
solution (50 mL) and brine (50 mL). The organic phase was dried
over MgSO4 and concentrated. The residue was puriﬁed by ﬂash
chromatography (cyclohexane/EtOAc 5:2) to provide 10 as a pale
yellow oil (950 mg, 90%). Rf¼ 0.56 (cyclohexane/EtOAc 5:2); 1H
NMR: d¼ 6.48 (d, J¼ 1.6 Hz, 1H; H4), 5.82 (ddt, J¼ 6.4, 10.3, 17.0 Hz,
1H; CH]CH2), 5.78 (ddt, J¼ 6.4, 10.3, 17.0 Hz, 1H; CH]CH2), 5.29
(qd, J¼ 5.8, 6.4 Hz, 1H; H5), 5.08 (dd, J¼ 1.6, 17.0 Hz, 1H; CH]CH2),
5.05 (dd, J¼ 1.6, 17.0 Hz,1H; CH]CH2), 5.02 (dd, J¼ 1.6, 10.3 Hz,1H;
CH]CH2), 5.00 (dd, J¼ 1.6, 10.3 Hz, 1H; CH]CH2), 3.28 (dd, J¼ 1.6,
5.8 Hz, 1H; H3), 2.80 (m, 2H; NCOCH2), 2.40 (m, 4H; OCOCH2 and
CH2C¼ C), 2.34 (m, 2H; CH2C¼ C), 2.11 (s, 3H; OCOCH3), 1.39 (d,
J¼ 6.4 Hz, 3H; CH3–CHO); 13C NMR: d¼ 171.7 (OCOCH2), 169.2 (C6),
168.8 (OCOCH3), 162.2 (C2), 136.2 (CH]CH2), 135.9 (CH]CH2),
115.9 (CH]CH2), 115.6 (CH]CH2), 74.5 (C4), 65.6 (C5), 62.5 (C3),
35.7 (NCO–CH2), 33.3 (OCOCH2), 28.6 (CH2C]C), 27.4 (CH2C]C),
20.6 (OCOCH3), 18.1 (CH3CHO); IR: n¼ 1806, 1742, 1722, 1642,
1313 cm1; HR-ESI-TOF-Mass (positive-mode): m/z calcd for
C17H23NO6þNa: 360.1423; found: 360.1412.
4.2.4. (E,11R,12R,14R)-14-(Acetoxy)-11-(methyl)-2, 9, 13-trioxo-10-
oxa-1-aza-bicyclo-[10.1.1]-tetradec-5-ene (11)
Grubbs catalyst of second generation was used (Scheme 6).
To a stirred solution of b-lactam 10 (355 mg, 1.05 mmol) in dry
CH2Cl2 (200 mL, [5 mM]) was added Grubbs catalyst (44.7 mg,
0.053 mmol). The reaction was performed at room temperature
under an argon atmosphere for 5 h. Then the solvent was removed
and the residue puriﬁed by ﬂash chromatography (cyclohexane/
EtOAc 5:2) to provide 11 as a white solid (268 mg, 83%). Rf¼ 0.54
(cyclohexane/EtOAc 5:3); m.p.¼117.8 C; 1H NMR: d¼ 6.53 (d,
J¼ 1.6 Hz, 1H; H4), 5.58 (qd, J¼ 1.8, 6.7 Hz, 1H; H5), 5.46 (m, 1H;
CH]CH), 5.40 (m, 1H; CH]CH), 3.27 (m, 1H; NCO–CH), 3.19 (dd,
J¼ 1.6, 1.8 Hz, 1H; H3), 2.46 (m, 1H; OCO–CH), 2.40 (m, 3H; NCO–
CHþ CH2C]C), 2.30 (m, 3H; OCO–CHþ C]C–CH2), 2.13 (s, 3H;
OCOCH3), 1.40 (d, J¼ 6.7 Hz, 3H; CH3CHO); 13C NMR: d¼ 171.6
(OCOCH2), 170.7 (NCOCH2), 169.1 (OCOCH3), 163.0 (C2), 130.4
(CH]C), 128.3 (C]CH), 74.1 (C4), 64.9 (C5), 62.7 (C3), 34.7
(NCOCH2), 33.7 (OCOCH2), 30.3 (CH2C]C), 28.2 (C]C–CH2), 20.8
(OCOCH3), 18.4 (CH3CO); IR: n¼ 1809,1742,1716 cm1; HR-ESI-TOF-
Mass (positive-mode): m/z calcd for C15H19NO6þNa: 332.1110;
found: 332.1101.
4.2.5. (11R,12R,14R)-14-(Acetoxy)-11-(methyl)-2, 9, 13-trioxo-10-
oxa-1-aza-bicyclo-[10.1.1]-tetradecane (12)
Precursor 11 (266 mg, 0.87 mmol) dissolved in EtOAc (15 mL)
was placed under H2 atmosphere (1 atm) at room temperature in
the presence of Pd catalyst (20 mg, 10% on C) for 17 h. Filtration and
concentration under vacuum furnished 12 as awhite solid (270 mg,
100%). Rf¼ 0.55 (cyclohexane/EtOAc 5:3); m.p.¼113.3 C; 1H NMR:
d¼ 6.50 (d, J¼ 1.3 Hz, 1H; H4), 5.53 (qd, J¼ 1.7, 6.9 Hz, 1H; H5), 3.22
(dt, J¼ 3.9, 14.1 Hz, 1H; NCOCH), 3.20 (m, 1H; H3), 2.34 (dt, J¼ 4.7,
14.1 Hz, 1H; NCOCH), 2.22–2.31 (m, 2H; OCOCH2), 2.10 (s, 3H;
OCOCH3), 2.01 (m, 1H), 1.76 (m, 1H), 1.60 (m, 1H), 1.49 (m, 1H), 1.38
(d, J¼ 6.9 Hz, 3H; CH3CHO), 1.19–1.35 (m, 4H); 13C NMR: d¼ 171.9
(OCOCH2), 171.1 (NCOCH2), 169.0 (OCOCH3), 163.8 (C2), 74.8 (C4),
65.4 (C5), 62.5 (C3), 32.9 (NCOCH2), 32.7 (OCOCH2), 25.6 (CH2), 25.4
(CH2), 25.3 (CH2), 25.1 (CH2), 20.8 (OCOCH3), 18.3 (CH3CHO); IR:
n¼ 1807, 1743, 1716 cm1; HR-ESI-TOF-Mass (positive-mode): m/z
calcd for C15H21NO6þNa: 334.1267; found: 334.1252.
4.3. Single-crystal X-ray crystallography
Compound 11 was recrystallized from ether/acetone (slow






Scheme 6. Grubbs catalyst.
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collected at 298(2) K with aMAR345 image plate detector usingMo
Ka (l¼ 0.71069 Å) monochromatized radiation. The unit cell
parameters were reﬁned using all the collected spots after the
integration process. Fig. 1 is drawn in the ORTEP style [69]. The
structure was solved by direct methods with SHELXS97 and reﬁned
by full-matrix least-squares on F2 using SHELXL97 [70]. All the non-
hydrogen atoms were reﬁnedwith anisotropic temperature factors.
The hydrogen atoms were calculated with AFIX and included in the
reﬁnement with a common isotropic temperature factor. The
structure has been deposited within the Cambridge Crystallo-
graphic data Centre, no CCDC 684061.
Crystal system¼monoclinic; space group¼ P21; unit cell
dimensions: a¼ 9.396(3) Å; b¼ 9.161(3) Å; c¼ 9.815(3) Å; vol-
ume¼ 819.0(5) Å3; Z¼ 2; Dx¼ 1.25 g cm3.
A total of 10 605 reﬂections were collected of which 1962 were
independent (Rint¼ 0.049) 1859 observed reﬂections (I> 2.5s(I));
2q max¼ .44.5; ﬁnal R¼ 0.046 (all data); wR2¼ 0.117; S¼ 1.09;
largest peak and hole 0.14, 0.14 e Å3.
4.4. NMR kinetic study
Phosphate buffer (1 mL, 50 mM, pH 8 adjusted with NaOH
solution) was freeze-dried and the residue was dissolved in D2O
(99.9%, 1 mL). A solution of azetidinone (25 mL, 8.102 M) in DMSO-
d6 was diluted with deuteriated phosphate buffer (475 mL) to give
a ﬁnal concentration of 4 mM. Chemical hydrolysis was followed by
1H NMR at 500 MHz as a function of time.
4.5. Theoretical evaluation
Conformational studies, calculations of heat of formation and
reactivity versus hydroxyl anion were carried out using the well-
established B3Lyp hybrid density functional [71] using the split
valence polarized 6-31G(d) basis set [72].
Reactivity versus serine enzyme models were performed at the
ab initio RHF level using the minimal basis set MINI-1’ [73]. All the
calculations have been performed with the suite of programs
Gaussian [74].
4.6. Biochemical evaluation
4.6.1. Assay with PPE
To a solution (2 mL) of substrate at 25 C (N-succinyl-L-alanyl-L-
alanyl-L-alanyl-p-nitroanilide; 300 mM in TRIS buffer, 100 mM, pH
7.5) and tested compound (20 mL; 102–104 M in N-methyl-
pyrrolidone (NMP)), or solvent (20 mL of NMP, for control), was
added porcine pancreatic elastase (PPE from Sigma at 0.35 mg/mL;
0.67 mL of 6 mM solution in acetate buffer, 50 mM, pH 5;
[E]¼ 200 nM). Absorbance at 410 nm, corresponding to the
appearance of p-nitroaniline (substrate hydrolysis product) was
measured with a Varian Cary 3 BIO spectrophotometer, as a func-
tion of time. Tested concentrations of inhibitors were 100, 50, 25
and 1 mM.
The reversibility of the inhibition was controlled by the incu-
bation/dilution method. Enzyme solution (67 mL) and inhibitor
solution (20 mL) were incubated during 20, 40 and 60 min before
the addition of substrate solution (2 mL). Absorbance at 410 nm for
different concentrations of inhibitor (100, 50, 25 and 1 mM) was
measured as a function of time.
4.6.2. Assay with TEM-1
The assay mixture was prepared at 25 C from the substrate
solution (nitroceﬁne at 1 mM in phosphate buffer, 100 mM, pH 7
containing 5% DMSO; 100 mL) and the tested compound (102–
104 M in DMSO; 10 mL), or solvent (10 mL DMSO, for control),
diluted in phosphate buffer (890 mL, 50 mM, pH 7). At t¼ 0, the
enzyme solution was added (class A b-lactamase TEM-1 at 1.2 mM
in phosphate buffer, 50 mM; pH 7; 1 mL, [E]¼ 1.2 nM). Absorbance
at 486 nm, corresponding to the appearance of nitroceﬁne hydro-
lysis product, was measured with a Varian Cary 3 BIO spectro-
photometer, as a function of time. Tested concentrations of
inhibitors were 100, 10 and 1 mM. TEM-1 enzyme was obtained
from the Unite´ de Biochimie (UCL, Louvain-la-Neuve), professors
J. Fastrez and P. Soumillon.
4.6.3. Assay with PBPs
The tested enzymes (R39, PBP2a, PBP5fm, PBP2x) were produced
and puriﬁed at the University of Lie`ge (Centre d’inge´nierie des
prote´ines, professors J-M. Fre`re, B. Joris and M. Galleni). The inhi-
bition studies were performed at 30 C in sodium phosphate buffer
(50 mM, pH 7) containing 5% to 10% DMF to ensure product solu-
bility. In the case of PBP2a and PBP5fm, 0.5 M NaCl was added.
Compounds were tested at 100 mM concentration; experiments
were performed in triplicate. Inhibitor (100 mM) and protein (0.8 or
2.5 mM) were mixed and incubated for 16 h. The residual free
protein was counter labeled with ﬂuorescein-labeled ampicillin
(25 mM) for 45 min. Then, the reaction was stopped by addition of
SDS-PAGE loading buffer and heating at 100 C for 4 min. The
reaction mixture was submitted to SDS-PAGE. The ﬂuorescent
complexes (formed by reaction of residual PBPs and ampicillin)
were visualised using a Molecular Imager FX and quantiﬁed with
the Quantity One Software of BIORAD. In each assay, background
ﬂuorescence was subtracted.
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